Wave Life Sciences Ltd. (WVE)
Automate Your Wheel Strategy on WVE
With Tiblio's Option Bot, you can configure your own wheel strategy including WVE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol WVE
- Rev/Share 0.6457
- Book/Share 1.0571
- PB 5.9126
- Debt/Equity 0.1374
- CurrentRatio 2.9528
- ROIC -0.6021
- MktCap 963337500.0
- FreeCF/Share -1.1156
- PFCF -5.3129
- PE -9.0431
- Debt/Assets 0.0818
- DivYield 0
- ROE -0.852
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | WVE | Cantor Fitzgerald | -- | Overweight | -- | $10 | April 29, 2025 |
| Initiation | WVE | Wedbush | -- | Outperform | -- | $18 | April 8, 2025 |
| Initiation | WVE | Jefferies | -- | Buy | -- | $26 | Feb. 25, 2025 |
| Upgrade | WVE | Raymond James | Outperform | Strong Buy | -- | $22 | Oct. 16, 2024 |
| Resumed | WVE | JP Morgan | -- | Overweight | $10 | $13 | Sept. 27, 2024 |
| Initiation | WVE | B. Riley Securities | -- | Buy | -- | $11 | Sept. 19, 2024 |
| Initiation | WVE | JP Morgan | -- | Overweight | -- | $10 | Sept. 9, 2024 |
News
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Wave Life Sciences (WVE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.24 per share a year ago.
Read More
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon …
Read More
Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates.
Read More
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
Read More
About Wave Life Sciences Ltd. (WVE)
- IPO Date 2015-11-11
- Website https://www.wavelifesciences.com
- Industry Biotechnology
- CEO Dr. Paul B. Bolno M.B.A., M.D.
- Employees 287